Pilot study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients with Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
- Conditions
- Myelodysplastic SyndromeAcute myeloid leukaemiaMedDRA version: 8.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromes
- Registration Number
- EUCTR2006-004452-20-GB
- Lead Sponsor
- King's College Hospital NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1.Availability of a HLA compatible sibling donor
2.Age >18 years
3.Myelodysplastic Syndromes with IPSS Intermediate-2 or High.
4.Poor risk acute myeloid leukaemia, de novo or transformed from MDS
5.Ineligibility for standard conditioning allograft due to age or co-existing morbidities
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1.Cardiac insufficiency requiring treatment or symptomatic coronary artery disease.
2.Hepatic disease, with AST > 2 times normal.
3.Severe hypoxaemia, pO2 < 70 mm Hg, with decreased DLCO < 70% of predicted; or mild hypoxemia, pO2 < 80 mm Hg with severely decreased DLCO < 60% of predicted.
4.Impaired renal function (creatinine > 2 times upper limit of normal or creatinine clearance < 50% for age, gender, weight).
5.Patients who have received previous treatment with Thymoglobuline
6.HIV-positive patients.
7.Female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants.
8.Life expectancy severely limited by diseases other than MDS or MPD.
9.Serious concurrent untreated infection
10.Patients with limited life expectancy for other reasons
11.Serious psychiatric/ psychological disorders
12.Absence of /inability to provide informed consent
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method